amsacrine has been researched along with Blast Phase in 7 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-two patients (mean age 41 years) in blast crisis or accelerated phase (AP) of chronic myelogenous leukemia (CML) were treated with cytosine arabinoside (Ara-C) 500 mg/m2 [intermediate dose] or 1000 mg/m2 [high dose] twice a day for 6 days and amsacrine (AMSA) 120 mg/m2 for 3 days." | 8.78 | Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine. ( Bauduer, F; Blanc, MC; Cadiou, M; Delmas-Marsalet, B; Delmer, A; Marie, JP; Rio, B; Zittoun, R, 1993) |
| "Twenty-two patients (mean age 41 years) in blast crisis or accelerated phase (AP) of chronic myelogenous leukemia (CML) were treated with cytosine arabinoside (Ara-C) 500 mg/m2 [intermediate dose] or 1000 mg/m2 [high dose] twice a day for 6 days and amsacrine (AMSA) 120 mg/m2 for 3 days." | 4.78 | Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine. ( Bauduer, F; Blanc, MC; Cadiou, M; Delmas-Marsalet, B; Delmer, A; Marie, JP; Rio, B; Zittoun, R, 1993) |
| " The intra-individual variation was much less, suggesting that dose adjustment based on pharmacokinetic data might be useful in the future." | 1.30 | In vitro cytotoxic drug activity and in vivo pharmacokinetics in childhood acute myeloid leukemia. ( Frost, BM; Larsson, R; Liliemark, E; Lönnerholm, G; Nygren, P; Peterson, C, 1999) |
| "Ten patients with acute myeloblastic leukemia (AML) in first relapse were treated with high-dose cytosine-arabinoside (ara-C, 3 g/m2/12 hours x 4) and amsacrine (150 mg/m2/day x 5)." | 1.29 | Treatment of relapsed acute myeloid leukemia using GM-CSF before intensive chemotherapy. ( Belloc, F; Bernard, P; Boiron, JM; Cony-Makhoul, P; Dumain, P; Lacombe, F; Laurent, G; Marit, G; Puntous, M; Reiffers, J, 1993) |
| " The pharmacokinetic data served as a guideline for in vitro toxicity tests on clonogenic bone marrow cells." | 1.29 | Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). ( Brons, P; de Witte, T; Knops, G; Linssen, P; Wessels, H, 1993) |
| "Thus, the CR rate for relapsed ANLL patients who received the higher doses of both agents was 40% (13 of 33)." | 1.28 | Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine. ( Dahl, GV; Grier, HE; Kalwinsky, DK; Mason, C; Mirro, J; Murphy, SB; Santana, VM, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Puntous, M | 1 |
| Lacombe, F | 1 |
| Dumain, P | 1 |
| Marit, G | 1 |
| Cony-Makhoul, P | 1 |
| Belloc, F | 1 |
| Boiron, JM | 1 |
| Laurent, G | 1 |
| Bernard, P | 1 |
| Reiffers, J | 1 |
| Bauduer, F | 1 |
| Delmer, A | 1 |
| Blanc, MC | 1 |
| Delmas-Marsalet, B | 1 |
| Cadiou, M | 1 |
| Rio, B | 1 |
| Marie, JP | 1 |
| Zittoun, R | 1 |
| Linssen, P | 1 |
| Brons, P | 1 |
| Knops, G | 1 |
| Wessels, H | 1 |
| de Witte, T | 1 |
| Meloni, G | 1 |
| Capria, S | 1 |
| Vignetti, M | 1 |
| Mandelli, F | 1 |
| Modena, V | 1 |
| Lönnerholm, G | 1 |
| Frost, BM | 1 |
| Larsson, R | 1 |
| Liliemark, E | 1 |
| Nygren, P | 1 |
| Peterson, C | 1 |
| Mirro, J | 1 |
| Kalwinsky, DK | 1 |
| Grier, HE | 1 |
| Santana, VM | 1 |
| Mason, C | 1 |
| Murphy, SB | 1 |
| Dahl, GV | 1 |
| Cervantes, F | 1 |
| López Guillermo, A | 1 |
| Rozman, M | 1 |
| Rozman, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia[NCT01690065] | Phase 2 | 46 participants (Anticipated) | Interventional | 2012-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amsacrine and Blast Phase
| Article | Year |
|---|---|
Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; C | 1993 |
6 other studies available for amsacrine and Blast Phase
| Article | Year |
|---|---|
Treatment of relapsed acute myeloid leukemia using GM-CSF before intensive chemotherapy.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Mar | 1993 |
Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L).
Topics: Acute Disease; Adult; Amsacrine; Blast Crisis; Bone Marrow; Bone Marrow Cells; Cell Division; Cell S | 1993 |
Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: regression of both diseases after autologous bone marrow transplantation.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Blast Crisis; | 1997 |
In vitro cytotoxic drug activity and in vivo pharmacokinetics in childhood acute myeloid leukemia.
Topics: Amsacrine; Antineoplastic Agents; Blast Crisis; Bone Marrow; Cell Survival; Child; Cytarabine; Doxor | 1999 |
Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; C | 1989 |
[Treatment with m-AMSA in the blast crisis of chronic myeloid leukemia].
Topics: Amsacrine; Blast Crisis; Drug Evaluation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; | 1988 |